Effects of cannabidiol on the signs and comorbidities of autistic spectrum disorder
Keywords:Autistic Spectrum Disorder; Treatment; Canabidiol; Cannabis.
Autism is considered a neuropsychiatric disorder, with development in early childhood, with losses in the following domains: social interaction, communication, restricted interests and stereotyped patterns of behavior. There is no established definitive treatment for autism, and the objective of pharmacological ones is the relief of specific signs. In general, traditionally used medications (atypical antipsychotics, selective serotonin reuptake inhibitors, stimulants and anticonvulsants) have several side effects, reflecting treatment discontinuation. Cannabidiol (CBD), a component of the Cannabis Sativa plant, is free from lysergic effects and has been used as an alternative to the treatment of Autistic Spectrum Disorder (ASD). The endocaninoid system acts in several physiological functions, accessing the therapeutic potential of CBD in the regulation of hyper or hypostimulated functions. Thus, a systematic review of clinical studies that used CBD in the treatment of signs and comorbidity of ASD was prepared. The databases used were PubMed and Medline, considering the following descriptors in each database: “autismo” and “treatment” and “cannabis”; and “autismo” and “treatment” and “canabidiol”, in the title and abstract. Manuscripts must be published in national and international journals, in English and Portuguese, and free full text. The selected manuscripts were read in full and relevant data extracted for analysis and interpretation. The results presented that overall, clinical trial participants have been shown to have improvements in all signs associated with the ASD considered in each study.
Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., Shmueli, D., Golan, D., & Castellanos, F. X. (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular autism, 12(1), 6. doi:10.1186/s13229-021-00420-2
Arberas, C., & Ruggieri, V. (2019). Autism. Genetic and biological aspects. Medicina (B Aires)., 79(Suppl 1):16-21. Spanish. PMID: 30776274.
Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D. O., Koren, G., & Berkovitch, M. (2019). Oral cannabidiol use in children with Autism Spectrum Disorder to treat related symptoms and co-morbidities. Frontiers in Pharmacology, 9, 1521. doi:10.3389/fphar.2018.01521
Chakrabarti, B., Persico, A., Battista, N., & Maccarrone, M. (2015). Endocannabinoid Signaling in Autism. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12(4), 837–847. doi:10.1007/s13311-015-0371-9
Cooray, R., Gupta, V., & Suphioglu, C. (2020). Current aspects of the endocannabinoid system and targeted thc and cbd phytocannabinoids as potential therapeutics for Parkinson's and Alzheimer's Diseases: a Review. Molecular Neurobiology, 57(11), 4878–4890. doi:10.1007/s12035-020-02054-6
Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Aswad, D., Notcutt, W. G., Martinez-Orgado, J., Robson, P. J., Rohrback, B. G., Thiele, E., Whalley, B., & Friedman, D. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791–802. doi:10.1111/epi.12631
Estrela, C. (2018). Metodologia Científica: Ciência, Ensino, Pesquisa. Editora Artes Médicas. Arte Med: Porto Alegre, 3ªEd, p.707.
Ferreira-Junior, N. C., Campos, A. C., Guimarães, F. S., Del-Bel, E., Zimmermann, P., Brum Junior, L., Hallak, J. E., Crippa, J. A., & Zuardi, A. W. (2020). Biological bases for a possible effect of cannabidiol in Parkinson's disease. Revista Brasileira de Psiquiatria (Sao Paulo, Brazil : 1999), 42(2), 218–224. doi:10.1590/1516-4446-2019-0460
Fleury-Teixeira, P., Caixeta, F. V., Ramires da Silva, L. C., Brasil-Neto, J. P., & Malcher-Lopes, R. (2019). Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An observational study of 18 participants undergoing compassionate use. Frontiers in Neurology, 10, 1145. doi:10.3389/fneur.2019.01145
Hollander, E., Dolgoff-Kaspar, R., Cartwright, C., Rawitt, R., & Novotny S. (2001). An open trial of divalproex sodium in autism spectrum disorders. Journal of Clinical Psychiatry, 62(7):530-4. doi:10.4088/jcp.v62n07a05
Kis, B., Ifrim, F. C., Buda, V., Avram, S., Pavel, I. Z., Antal, D., Paunescu, V., Dehelean, C. A., Ardelean, F., Diaconeasa, Z., Soica, C., & Danciu, C. (2019). Cannabidiol-from plant to human body: a promising bioactive molecule with multi-target effects in cancer. International Journal of Molecular Sciences, 20(23), 5905. doi:10.3390/ijms20235905
Linartevichi, V., Cury, R., & Nascimento, F. (2021). Possível utilização de canabinoides na Doença de Alzheimer: uma revisão. Fag Journal of Health, 3(2), 195-199. doi:10.35984/fjh.v3i2.365
Maneeton, N., Maneeton, B., Putthisri, S., Woottiluk, P., Narkpongphun, A., & Srisurapanont, M. (2018). Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatric Disease and Treatment, 14, 1811–1820. doi:10.2147/NDT.S151802
Mottron, L., & Bzdok, D. (2020). Autism spectrum heterogeneity: fact or artifact?. Molecular Psychiatry, 25(12), 3178–3185. doi:10.1038/s41380-020-0748-y
Nikolov, R., Jonker, J., & Scahill, L. (2006). Autistic disorder: current psychopharmacological treatments and areas of interest for future developments. Brazilian Journal of Psychiatry, 28 Suppl 1:S39-46. Portuguese. doi:10.1590/s1516-44462006000500006
Nunes, T. P., Nunes, L. P. ., Silva , A. N. A. ., Pirovani, B. O. ., Morábito , M. J. S. D. ., de Morais, L. A., Gruba, A. S. ., & Nunes , G. P. . (2021). Effects adverse of treatment with selective inhibitors of serotonin recaptation on the fetus and neonatals of mothers with gestational depression: A critical review. Research, Society and Development, 10(4), e11210413937. doi:10.33448/rsd-v10i4.13937
Oliveira, CR de A., & Souza, JC. (2021). Neurobiologia do autismo infantil. Research, Society and Development, 10 (1), e11910111495. doi:10.33448/rsd-v10i1.11495
Pacher, P., & Kunos, G. (2013). Modulating the endocannabinoid system in human health and disease--successes and failures. The FEBS Journal, 280(9), 1918–1943. doi:10.1111/febs.12260
Pretzsch, C. M., Voinescu, B., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Williams, S., Murphy, D. G., Daly, E., & McAlonan, G. M. (2019). The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology (Oxford, England), 33(9), 1141–1148. doi:10.1177/0269881119858306
Reddihough, D. S., Marraffa, C., Mouti, A., O'Sullivan, M., Lee, K. J., Orsini, F., Hazell, P., Granich, J., Whitehouse, A., Wray, J., Dossetor, D., Santosh, P., Silove, N., & Kohn, M. (2019). Effect of fluoxetine on obsessive-compulsive behaviors in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA, 322(16), 1561–1569. doi:10.1001/jama.2019.14685
Reece, A. S., & Hulse, G. K. (2019). Impacts of cannabinoid epigenetics on human development: reflections on Murphy et. al. 'cannabinoid exposure and altered DNA methylation in rat and human sperm' epigenetics 2018; 13: 1208-1221. Epigenetics, 14(11), 1041–1056. doi:10.1080/15592294.2019.1633868
Rubim, A. L., & Hora, A. F. L. T. da. (2020). Social skills training possibilities for adults with autism spectrum disorder: a systematic review. Research, Society and Development, 9(7), e414974287. doi:10.33448/rsd-v9i7.4287
Silva, C. O. da, Oliveira, S. A., Silva, W. C. da, Mendes, R. C., Miranda, L. S. C., Melo, K. C., Silva, R. A. da, Oliveira, T. M. P. de, Oliveira, C. de J. P., & Santos, M. E. de J. (2020). Benefits in using early intervention in children with autista spectrum disorder (ASD): an integrative review. Research, Society and Development, 9(7), e256972474. doi:10.33448/rsd-v9i7.2474
Silva, W. M. da, & Coelho, A. T. C. B. . (2021). The language acquisition process for children with autistic spectrum disorder: review article. Research, Society and Development, 10(1), e15010111584. doi:10.33448/rsd-v10i1.11584
Starowicz, K., & Finn, D.P. (2017). Cannabinoids and pain: sites and mechanisms of action. Advances in Pharmacology, 80:437-475. doi:10.1016/bs.apha.2017.05.003
Schleider, L.B., Mechoulam, R., Saban, N., Meiri, G., Novack, V. (2019). real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Science Report, 9(1):200. doi:10.1038/s41598-018-37570-y
How to Cite
Copyright (c) 2021 Flávia Cristina Osaku Minella; Vagner Fagnani Linartevichi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.